Project Grant HT94252510928
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,508,132.00 in funding to the University of Rhode Island (URI) to conduct research on the use of bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. The award period runs from September 30, 2025 to September 29, 2029. The research aims to develop innovative medical...
- The U.S. Defense Health Agency awarded a $715,213 Project Grant to the Veterans Education and Research Association of Northern New England, Inc. (VERANNE) to conduct research on using bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. This award is part of the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research aimed at transforming healthcare for...
- The Defense Health Agency awarded a $1,117,352 Project Grant to Trustees of Boston University's Boston University Medical Campus to develop a novel and practical intervention for detoxification of per- and polyfluoroalkyl substances (PFAS) in humans. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports the university's research to transform health care for Service Members and the public through innovative biomedical research. As part of the...
- This federal Project Grant award of $660,283.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Carnegie Mellon University to develop a high-throughput bioanalytical and machine learning approach for prioritizing bioaccumulative per- and polyfluoroalkyl substances (PFAS) in complex mixtures. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing...
- The University of Louisville Office of Research & Innovation Division was awarded a $1,368,092 Project Grant by the Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project investigating the "Liver and Systemic Effects of Toxic Exposures". The research aims to transform healthcare for Service Members and the American public through innovative biomedical research. The...
- This $701,121 federal Project Grant award from the Department of Defense's Defense Health Agency, issued under the Military Medical Research and Development program (CFDA 12.420), supports research on the ovarian-disrupting effects and mechanisms of per- and polyfluoroalkyl substances (PFAS). The project is being conducted by Rutgers, The State University of New Jersey's RBHS-School of Nursing over a 3-year period from September 2023 to September 2026. The research aims to develop a better...
- The University of Illinois was awarded a $798,912 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate how PFAS (per- and polyfluoroalkyl substances) exposures can reprogram prostate stem cells and drive carcinogenesis and cancer progression. The 3-year project, running from July 1, 2023 to June 30, 2026, will advance scientific understanding of how environmental PFAS exposures may...
- This $864,533 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Metis Foundation, a non-profit organization based in San Antonio, Texas. The purpose of this 3-year award, with a performance period from September 30, 2025 to September 29, 2028, is to conduct research on the association between PFAS and other toxic military exposures and pancreatic cancer risk in a military population. The Metis Foundation, which...
- This Project Grant award, titled "TARGETING LYSOSOMAL PATHWAYS TO IMPROVE HOST IMMUNITY POST CORONAVIRAL INFECTIONS," is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The $1,572,933 award to the University of Pittsburgh is effective from January 1, 2025 through December 31, 2028. The objective of this research project is to investigate novel approaches for improving host immune responses following coronavirus...
- This $774,620 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) is funding a research project titled "ACUTE AND SUB-CHRONIC EXPOSURES TO DIOXIN AND DIOXIN-LIKE COMPOUNDS IN LIVER DISEASE: THE ROLE OF SEX AND AGE" at the University of Louisville. The 3-year research project, with a period of performance from Sep 30, 2023 to Sep 29, 2026, will investigate the impacts of acute and sub-chronic exposures to dioxin and...
This federal Project Grant award of $1,293,748.00, made by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to investigate the use of bile acid-binding resins to decrease systemic per- and polyfluoroalkyl substance (PFAS) levels and improve serum lipid profiles in veterans. The research will be conducted by the University of Louisville's Office of Research & Innovation over a performance period from September 30, 2025 to September 29, 2029. This project aims to develop innovative medical solutions that address critical health challenges relevant to military personnel and civilian populations. The Defense Health Agency, as the primary funding agency, seeks to transform healthcare for service members and the public through impactful biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 7/31/25 |